巻号一覧
49 巻, 11 号
「光線力学療法の最先端」特集号
選択された号の論文の7件中1～7を表示しています
- |<
- <
- 1
- >
- >|
「光線力学療法の最先端」特集号
特集
レーザー解説
-
松浦 祐司2021 年 49 巻 11 号 p. 602-
発行日: 2021年
公開日: 2024/04/12
ジャーナル フリーIn photodynamic therapy (PDT)，after a photosensitizer is administered that accumulates in tumor tissue and new blood vessels, a laser beam is irradiated around the tumor to cause a photochemical reaction. This reaction generates active oxygen and causes necrosis in tumor tissue. The first PDT was developed in Japan, and a first-generation PDT was introduced in 1996 using porphymer sodium and an excimer dye laser. In 2004, the second-generation PDT was introduced that used talaporfin sodium and a small diode laser. Its use was included in insurance coverage. In 2014, its use was covered by insurance as a treatment for malignant brain tumor and for locally residual recurrent esophageal cancer in 2015. New treatment targets, new light irradiation devices, and new photosensitive drugs are being developed internationally. In this special issue, researchers in various PDT fields explain their latest research and future prospects.抄録全体を表示PDF形式でダウンロード (239K) -
臼田 実男2021 年 49 巻 11 号 p. 604-
発行日: 2021年
公開日: 2024/04/12
ジャーナル フリーPhotodynamic therapy (PDT) consists of using a tumor specific photosensitizer and low power laser irradiation to induce production of reactive oxygen species in cancer cells. PDT is not like burning the cancer cells and a minimally invasive treatment. In Japan, PDT is recommended to treat early stage nonsmall cell lung cancer that is located around pulmonary hilar lesion. PDT was first approved for centrally located early lung cancers in 1994, and in 2010 PDT was approved for the improvement of the respiratory tract obstruction caused by advanced lung cancers, for the improvement of the quality of life (QOL), and for progressive lung cancer. Because smoking is the greatest cause of centrally located early lung cancers, most patients with this disease suffer from poor cardio-pulmonary function. As PDT exercises minimal invasiveness, it can be performed with safety. Also its high effectiveness has been proven by its clinical tests. Recently, a multicenter clinical trial was the world’s first trial of talaporfin-PDT for c-stage IA peripheral lung cancer. PDT was found to be a feasible and non-invasive treatment modality for early peripheral lung cancers. In the future, talaporfin-PDT could become a useful treatment modality for non-invasive adenocarcinomas, and the standard option for stage IA peripheral lung cancers.抄録全体を表示PDF形式でダウンロード (381K) -
秋元 治朗2021 年 49 巻 11 号 p. 607-
発行日: 2021年
公開日: 2024/04/12
ジャーナル フリーPhotodynamic therapy (PDT) was approved to be covered by health insurance in Japan in 2013, as an additional intraoperative local treatment for invasive tumor cells after maximum safe resection of the primary malignant brain tumors. Seven years have passed, and PDT is conducted in 26 academic centers in Japan, and more than 200 cases receive the benefit of PDT per year. This review provides the latest knowledges of PDT for malignant brain tumors, illustrating how PDT is applied in the clinical practice in the world.抄録全体を表示PDF形式でダウンロード (817K) -
野本 貴大2021 年 49 巻 11 号 p. 611-
発行日: 2021年
公開日: 2024/04/12
ジャーナル フリーExtending the application of photodynamic therapy (PDT) requires development of photosensitizers (PSs) that can selectively accumulate within target tumors. Although researchers have developed various kinds of PSs in recent years, only a few of them have reached the clinical development stage. This article reviews the characteristics of clinically approved PSs to elucidate the physicochemical properties which are necessary for their practical application and examines recent trends in the development of drug delivery systems (DDSs) for PDT. In addition, this article introduces polymer-PS conjugates developed in our lab which target acidic tumorous pH and the tumor-associated vasculature. Our polymer- PS conjugates exhibited selective tumor accumulation after intravenous injection and a significantly enhanced PDT effect in subcutaneous tumor models. Our DDSs also unveiled important fundamental knowledge in photochemical damage to normal and tumor tissues, which may contribute to the future design of DDSs for PDT.抄録全体を表示PDF形式でダウンロード (758K) -
西村 隆宏 , 守 顕太, 粟津 邦男2021 年 49 巻 11 号 p. 616-
発行日: 2021年
公開日: 2024/04/12
ジャーナル フリーThe computational simulation of an action mechanism in photodynamic therapy (PDT) allows for the quantitative understanding of treatment outcomes that depend on various variables related to clinical treatment conditions. To simulate a PDT effect, a singlet oxygen dose, which is the main factor that causes cytotoxicity for treatment, is used for an index that describes the effect of PDT treatment. Based on the singlet oxygen dose, the PDT treatment effect can be simulated by calculating the distribution of light irradiation, calculating the singlet oxygen dose, and determining the necrosis area based on the singlet oxygen dose in biotissues. This paper introduces computational simulation methods to estimate photodynamic therapy and describes an overview of the computational evaluation of interstitial photodynamic therapy for malignant brain tumors.抄録全体を表示PDF形式でダウンロード (833K) -
小川 恵美悠2021 年 49 巻 11 号 p. 621-
発行日: 2021年
公開日: 2024/04/12
ジャーナル フリーPhotodynamic therapy (PDT) is a minimally invasive therapy that utilizes singlet oxygen produced by irradiating a tumor-accumulating photosensitizer with excitation light. One of the challenges of PDT is photosensitivity caused by residual photosensitive drugs in the skin. Exposure of skin with residual photosensitive drugs to sunlight causes photosensitivity such as erythema, blistering, and hyperpigmentation of the skin. The light-blocking period established to prevent photosensitivity does not indicate the duration of hospitalization, but inpatient observation is often performed. Decreased patient QOL due to light shielding, such as progression of amnesia during light shielding hospitalization in elderly patients, is a problem. This article reviews the status of photosensitivity and a quantitative monitoring system for drug concentrations in skin tissues to obtain scientific evidence for discharge timing and home management in PDT.抄録全体を表示PDF形式でダウンロード (892K)
レーザーオリジナル
-
シャフケティ アリフ, ラゴロサス ノフェル, 椎名 達雄2021 年 49 巻 11 号 p. 625-
発行日: 2021年
公開日: 2024/04/12
ジャーナル フリーLaser beam propagation in highly scattering media has attracted much attention for optical sensing fields. To further explore the characteristics of beam propagation, we investigate the propagation property of an annular beam in a highly scattering media for increasing the sensing limitation in such scattering conditions. In this work, propagation of partially blocked annular beam in free space is simulated to show self-transformation of non-diffractive beam which keeps its main central energy up to far lengths. Using a fan-like obstacle with different apex angles, propagation experiments of partially blocked annular beam in scattering media were conducted. The scattering light is measured at different receiving distances to demonstrate that the central peak intensity of this scattered light is a non-diffractive beam. We discussed that the change of the intensity profile of scattered light can be used to infer the position and the relative sizes of the obstacles.抄録全体を表示PDF形式でダウンロード (1300K)
- |<
- <
- 1
- >
- >|